Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading research-driven pharmaceutical company, has once again received the World Health Organization (WHO) Good Distribution Practices (GDP) Certification for its Supply Chain Unit-II in Baddi, Himachal Pradesh, from Société Générale de Surveillance (SGS) — the world’s foremost inspection, testing, and certification authority.
Awarded basis a comprehensive audit, the certification underscores Venus Remedies’ unwavering commitment to global pharmaceutical quality norms and best practices in distribution. It highlights the company’s consistent adherence to international protocols across its end-to-end operations—from manufacturing to last-mile delivery.
“The WHO GDP certification is a strategic affirmation of our ability to deliver high-quality, safe, and effective medicines with precision, accountability, and transparency. Earned through a rigorous, independent audit, this recognition is a testament to our operational discipline, culture of continuous improvement, and the collective commitment of our teams to set new benchmarks for excellence in pharmaceutical delivery in India and globally,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.
As part of its supply chain transformation, Venus Remedies has adopted a 360-degree digital logistics model, implementing IoT-enabled systems to monitor key shipment conditions—such as temperature, humidity, and location alerts—in real-time. The company has also developed proprietary warehousing algorithms to optimize cartonization and shipping workflows, halving delivery time while reducing costs.
Extending its reach directly to pharmacies and small retailers, Venus Remedies now operates a parallel online delivery system backed by real-time order tracking, digital payment reconciliation, and live customer support—strengthening its market presence and customer engagement in the country.
“At Venus Remedies, we believe that quality assurance must be embedded into every layer of operations—from R&D to real-time delivery. The WHO GDP accreditation validates our investment in cutting-edge logistics and reflects our strategic vision to be a globally trusted partner in healthcare,” said Mr. Peeyush Jain, Deputy Managing Director, Venus Remedies.
The company’s robust compliance credentials also include more than 25 Good Manufacturing Practices (GMP) certifications, including the most recent approval from Ukraine, for its globally benchmarked manufacturing facilities. Together with WHO GDP, these recognitions underscore Venus Remedies’ unwavering commitment to quality, safety, and regulatory integrity across every stage of the pharmaceutical value chain.